Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 9/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920928 | 0.89 | ESR1 (0.36) | CETPKMT2AMEN1LMNAGAA | |
| SCHEMBL2922786 | 0.89 | HTT (0.36) | CETPHRH4HTR3AKMT2AMEN1 | |
| SCHEMBL2911656 | 0.89 | MEN1 (0.34) | CETPHRH4KMT2AMEN1LMNA | |
| SCHEMBL2916952 | 0.89 | PDE11A (0.42) | HRH4KMT2AMEN1LMNAGAA | |
| SCHEMBL3027474 | 0.87 | CHRNA10 (0.37) | CETPHRH4KMT2AMEN1LMNA | |
| SCHEMBL3022088 | 0.85 | MAPT (0.41) | HRH4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL2921386 | 0.80 | MAPT (0.47) | KMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL2913055 | 0.80 | KHK (0.43) | CETPKMT2AMEN1LMNAKDM4E | |
| SCHEMBL588859 | 0.79 | ALDH1A1 (0.44) | CETPHTR3AKMT2ALMNAGAA | |
| SCHEMBL4071055 | 0.79 | CETP (0.36) | CETPHRH4HTR3AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511045-B2 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | DPYD, DHODH, DPM1 | CETP 3159/4885HRH4 88/4885HTR3A 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.